257 related articles for article (PubMed ID: 20860349)
1. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Jan; 1369():203-7. PubMed ID: 21047502
[TBL] [Abstract][Full Text] [Related]
3. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
J Pharmacol Exp Ther; 2010 Jun; 333(3):961-9. PubMed ID: 20233799
[TBL] [Abstract][Full Text] [Related]
4. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Drug Metab Dispos; 2012 Feb; 40(2):329-35. PubMed ID: 22065691
[TBL] [Abstract][Full Text] [Related]
5. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Drug Metab Dispos; 2010 Apr; 38(4):566-72. PubMed ID: 20075191
[TBL] [Abstract][Full Text] [Related]
7. CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
Biotechnol Bioeng; 2011 Jan; 108(1):186-96. PubMed ID: 20803562
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.
Boado RJ; Zhou QH; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Feb; 7(1):237-44. PubMed ID: 19921848
[TBL] [Abstract][Full Text] [Related]
9. Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.
Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Mar; 1382():315-20. PubMed ID: 21276430
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2010 Nov; 1360():193-7. PubMed ID: 20833153
[TBL] [Abstract][Full Text] [Related]
11. Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.
Chang R; Al Maghribi A; Vanderpoel V; Vasilevko V; Cribbs DH; Boado R; Pardridge WM; Sumbria RK
Mol Pharm; 2018 Nov; 15(11):4963-4973. PubMed ID: 30252487
[TBL] [Abstract][Full Text] [Related]
12. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
Zhou QH; Boado RJ; Pardridge WM
J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
[TBL] [Abstract][Full Text] [Related]
13. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
[TBL] [Abstract][Full Text] [Related]
14. Brain-penetrating tumor necrosis factor decoy receptor in the mouse.
Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
Drug Metab Dispos; 2011 Jan; 39(1):71-6. PubMed ID: 20884844
[TBL] [Abstract][Full Text] [Related]
15. Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice.
Sun J; Boado RJ; Pardridge WM; Sumbria RK
Mol Pharm; 2019 Aug; 16(8):3534-3543. PubMed ID: 31199881
[TBL] [Abstract][Full Text] [Related]
16. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Aug; 97(6):1376-86. PubMed ID: 17286273
[TBL] [Abstract][Full Text] [Related]
17. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.
Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2010 Jan; 21(1):151-6. PubMed ID: 20000684
[TBL] [Abstract][Full Text] [Related]
18. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Biotechnol Bioeng; 2008 Feb; 99(2):475-84. PubMed ID: 17680664
[TBL] [Abstract][Full Text] [Related]
19. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
[TBL] [Abstract][Full Text] [Related]
20. Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice.
Yang J; Sun J; Castellanos DM; Pardridge WM; Sumbria RK
Mol Pharm; 2020 Aug; 17(8):2831-2839. PubMed ID: 32579360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
